Agios Pharmaceuticals AGIO

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$1.43 (-4.21%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Agios Pharmaceuticals (AGIO)
    Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $32.38

    • Market Cap

      $1.86 Billion

    • Price-Earnings Ratio

      2.73

    • Total Outstanding Shares

      57.30 Million Shares

    • Total Employees

      488

    • Dividend

      No dividend

    • IPO Date

      July 24, 2013

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      88 sidney street, Cambridge, MA, 02139

    • Homepage

      https://www.agios.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow$-11.96 Million
    Net Cash Flow, Continuing$-11.96 Million
    Net Cash Flow From Financing Activities$14.44 Million
    Net Cash Flow From Investing Activities$363.44 Million
    Net Cash Flow From Operating Activities, Continuing$-389.84 Million
    Net Cash Flow From Investing Activities, Continuing$363.44 Million

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Basic Earnings Per Share$11.86
    Income/Loss From Continuing Operations After Tax$673.73 Million
    Basic Average Shares$56.81 Million
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
    Operating Income/Loss$-425.74 Million
    Income Tax Expense/Benefit$44.24 Million

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$672.65 Million
    Other Comprehensive Income/Loss$672.65 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$672.65 Million

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Other Current Liabilities$34.58 Million
    Cash$1.50 Billion
    Inventory$27.62 Million
    Equity Attributable To Parent$1.54 Billion
    Wages$29.93 Million
    Fixed Assets$11.68 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AGIO from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.